2022年11月17日,

风险资本新闻|私人股本风险资本目录|私人股本目录风险资本公司列表/风险资本和私人股本公司和出版来源自1998年以来,VCPro数据库是最可靠的、最新的和负担得起的风险资本目录2022最新更新版现在可用!(2022年7月更新)VCPro数据库2022年25日版-一个可下载的和可搜索的数据库与风险资本6800 +全球风险资本和私人股本公司。最可靠的、最新的和负担得起的风险资本的目录。VCPro数据库可以在Windows和macOS版本。自1998年以来,它已经出版。Torigen制药宣布完成1300万美元的筹资法明顿,康涅狄格州,11月16日,2022年,Torigen制药、公司,commercial-stage动物卫生生物制剂公司今天宣布,它已关闭了1300万美元的A1轮Werth家人投资伙伴,有限责任公司和康涅狄格创新,Inc .,使总提出的公司1800万美元。现有投资者翡翠开发经理、Gaingels Kema基金,圣母院大学SoGal Ventures和康州大学创新基金,公司参与了一轮。在这一轮新投资者还包括硬木资本和资本优势。“我们的目标是创建一个兽医行业首个肿瘤工具箱,”阿什利Kalinauskas说,首席执行官和共同创始人Torigen药品。“这轮融资将使我们能够继续开发新产品,利用我们的管道。 We are excited to work with all our investors as we expand our platform and continue to help the millions of pets diagnosed with cancer and other immune-mediated diseases each year.” “Our investment in Torigen is grounded in the same values and principles that guide us at Werth Ventures,” said Musan Duric, Investment Portfolio Manager, Werth Ventures. “As a family office, we focus on growing the good in business and life, supporting women entrepreneurs, and championing change within the animal health market. Torigen’s lead product, VetiVax, is a prime example of the company’s ability to deliver innovative products and access the veterinary market. We’re committed to seeing Torigen succeed and look forward to accompanying the entire team on its journey.” “Torigen is a transformative animal health tech company that creates personalized cancer immunotherapies, making effective cancer treatment more accessible and affordable for pet owners,” said Neil Cohen, Chairman, Emerald Development Managers. “The work Torigen has done to date is exceptional. The team has developed a deep understanding of animal oncology, allowing them to develop new treatments to cover additional animal health conditions. We look forward to supporting Torigen’s growth and to collaborating with Connecticut Innovations, Werth, and all those invested in the company’s success.” To meet the market’s strong demand, Torigen is now recruiting a skilled salesforce. Postings for open roles can be found at http://www.torigen.com. About Torigen Pharmaceuticals Inc: Torigen is transforming pet cancer treatment by harnessing the pet's immune system to create personalized cancer immunotherapies, making pet cancer treatment more accessible and more affordable. Torigen recognizes the instrumental role pets play in our families and is determined to extend the lives of companion animals despite a cancer diagnosis. With over 50% of all dogs over the age of 10 dying from cancer, Torigen is dedicated to providing affordable and effective cancer care solutions for all companion animals. Torigen is a spin-out from the University of Notre Dame and backed by Werth Family Investment Associates, Connecticut Innovations, Emerald Development Managers, Ironwood Capital, Advantage Capital, The University of Connecticut, The University of Notre Dame, SoGal Ventures, Gaingels, and other prominent investors. For more information visit http://www.torigen.com.